Spondyloarthritis & psoriatic arthritis
Impact of inflammation and anti-inflammatory therapies on the incidence of major cardiovascular events in patients with ankylosing spondylitis: A population-based study
Authors' conclusion
High inflammatory burden was an independent predictor associated with an increased risk of MACE, while the use of SLZ might reduce risk of incident MACE in patients with AS.
Study context
- Population
- Ankylosing spondylitis (AS) patients from a territory-wide database, 2006–2015, followed until end of 2018 (mean age 45.2 ± 15.0 years; male 76.1 %)
- Participants
- 3,827 patients23,275 person-years
- Exposure
- Inflammatory burden (ESR, CRP) and anti-inflammatory therapies vs none, for incident major adverse cardiovascular events (MACE)
- Outcome
- First occurrence of MACE
Methodological detailspopulation-based, territory-wide database, multivariate time-varying Cox proportional hazard models
- Population-based
- Territory-wide database
- Multivariate time-varying Cox proportional hazard models
Main finding
As reported in the abstract
First MACE
- Patients developing a first MACE
- 135 (3.5 %)
- ESR, adjusted HR
- 1.02
- ESR ≥30 mm/h, adjusted HR
- 1.94
- CRP level, adjusted HR
- 1.14
- CRP >3 mg/dl, adjusted HR
- 5.43
- Sulfasalazine (SLZ) use, adjusted HR (protective)
- 0.41-0.52
Observational data: associations, not effects.
Further findings
Univariate associations with MACE
- Elevated ESR and CRP and GC use associated with significantly higher risk of MACE
- SLZ, bDMARDs and non-COX-IIi use associated with reduced risk of MACE
- Univariate analyses
Original publication
Impact of inflammation and anti-inflammatory therapies on the incidence of major cardiovascular events in patients with ankylosing spondylitis: A population-based study. Semin Arthritis Rheum. Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →